Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji, +16

Liver Cancer

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, +23

Cancer Medicine

Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, +14

Digestive Diseases

Surgical OncologySorafenib TreatmentPathologyHepatic FunctionHcc Patients +19

Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection

Kentaro Matsuura, Hiromi Sawai, Kazuho Ikeo, +43

Gastroenterology

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, +19

Cancer Medicine

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada, +80

European Journal of Cancer

OncologyHepatologyMedicinePathologyBevacizumab Versus Lenvatinib +6

Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, +28

Liver International

Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, +16

Hepatology Research

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma

Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, +25

Oncology

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, +38

Hepatology Research